These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 12406912

  • 1. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.
    Blood; 2003 Feb 15; 101(4):1270-6. PubMed ID: 12406912
    [Abstract] [Full Text] [Related]

  • 2. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
    Mata JF, Scrideli CA, Queiroz RP, Mori BO, Emerenciano M, Pombo-de-Oliveira MS, Tone LG.
    Braz J Med Biol Res; 2006 Nov 15; 39(11):1417-23. PubMed ID: 17146554
    [Abstract] [Full Text] [Related]

  • 3. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 4. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
    Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R.
    Leukemia; 2004 Mar 15; 18(3):521-9. PubMed ID: 14712291
    [Abstract] [Full Text] [Related]

  • 5. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
    Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ.
    Br J Cancer; 2005 Dec 12; 93(12):1388-94. PubMed ID: 16333246
    [Abstract] [Full Text] [Related]

  • 6. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
    Català A, Pastor-Anglada M, Caviedes-Cárdenas L, Malatesta R, Rives S, Vega-García N, Camós M, Fernández-Calotti P.
    Oncotarget; 2016 Aug 02; 7(31):49786-49799. PubMed ID: 27391351
    [Abstract] [Full Text] [Related]

  • 7. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P.
    Pharmacogenomics; 2015 Jul 02; 16(8):877-90. PubMed ID: 26083014
    [Abstract] [Full Text] [Related]

  • 8. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R.
    Blood; 2010 Feb 04; 115(5):1018-25. PubMed ID: 19965632
    [Abstract] [Full Text] [Related]

  • 9. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT, Jiang SY, Li BS, Yang LL.
    Zhonghua Er Ke Za Zhi; 2008 Apr 04; 46(4):276-80. PubMed ID: 19099730
    [Abstract] [Full Text] [Related]

  • 10. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage.
    Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG, Kanerva J, Schmiegelow K, Larsson R, Lönnerholm G, Nordic Society for Paediatric Haematology and Oncology.
    Br J Haematol; 2005 Apr 04; 129(2):189-98. PubMed ID: 15813846
    [Abstract] [Full Text] [Related]

  • 11. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ, Schneider P, Pieters R, Stam RW.
    Eur J Cancer; 2015 Sep 04; 51(14):2008-21. PubMed ID: 26188848
    [Abstract] [Full Text] [Related]

  • 12. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
    Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, Pieters R.
    Leukemia; 2004 Jan 04; 18(1):78-83. PubMed ID: 14574327
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS.
    Cancer Chemother Pharmacol; 1989 Jan 04; 24(4):203-10. PubMed ID: 2473850
    [Abstract] [Full Text] [Related]

  • 14. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M, Yoshida S.
    Jpn J Cancer Res; 1987 Aug 04; 78(8):851-7. PubMed ID: 3115933
    [Abstract] [Full Text] [Related]

  • 15. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
    Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.
    Haematologica; 2013 Jun 04; 98(6):937-44. PubMed ID: 23403319
    [Abstract] [Full Text] [Related]

  • 16. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M, Inukai T, Miyake K, Tanaka Y, Kagami K, Abe M, Goto H, Minegishi M, Iwamoto S, Sugihara E, Watanabe A, Somazu S, Shinohara T, Oshiro H, Akahane K, Goi K, Sugita K.
    Cancer Med; 2018 Apr 04; 7(4):1297-1316. PubMed ID: 29473342
    [Abstract] [Full Text] [Related]

  • 17. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
    Kanno S, Hiura T, Ohtake T, Koiwai K, Suzuki H, Ujibe M, Ishikawa M.
    Clin Chim Acta; 2007 Feb 04; 377(1-2):144-9. PubMed ID: 17097625
    [Abstract] [Full Text] [Related]

  • 18. MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.
    Stam RW, Hubeek I, den Boer ML, Buijs-Gladdines JG, Creutzig U, Kaspers GJ, Pieters R.
    Leukemia; 2006 Jan 04; 20(1):179-82. PubMed ID: 16307022
    [No Abstract] [Full Text] [Related]

  • 19. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
    Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW.
    Cancer Res; 2004 Jan 15; 64(2):728-35. PubMed ID: 14744791
    [Abstract] [Full Text] [Related]

  • 20. Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity.
    Tang J, Xie X, Zhang X, Qiao X, Jiang S, Shi W, Shao Y, Zhou X.
    Front Biosci (Landmark Ed); 2012 Jan 01; 17(2):569-74. PubMed ID: 22201761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.